CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Aceclofenac

醋氯芬酸 杂质对照品Aceclofenac Impurities

EP19 个杂质条目19 impurity entries

本页汇总 醋氯芬酸 的 19 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 19 impurity reference standards of Aceclofenac with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 醋氯芬酸(Aceclofenac)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesA New Stability-Indicating RP-HPLC Method for Simultaneous Quantification of Diacerein and Aceclofenac in Novel Nanoemulgel Formulation and Commercial Tablet Dosage Form in the Presence of their Major Degradation Products Using DoE Approach
    Journal of chromatographic science · 2023 · Kazi TM, Dandagi PM  ·  PMID 37194660  ·  DOI
  2. 杂质研究Impurity studiesRP-LC gradient elution method for simultaneous determination of thiocolchicoside, aceclofenac and related impurities in tablet formulation
    Journal of pharmacy & bioallied sciences · 2014 · Karbhari PA et al.  ·  PMID 25400407  ·  DOI
  3. 杂质研究Impurity studiesValidated stability-indicating assay method for simultaneous determination of aceclofenac and thiocolchicoside using RP-HPLC
    Drug research · 2014 · Samanthula G et al.  ·  PMID 24310363  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisSynthesis of aceclofenac and L-Arginine salt, characterization and bioactivities
    Journal of pharmaceutical sciences · 2025 · Shah M et al.  ·  PMID 40562175  ·  DOI
  • 合成方法SynthesisAceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes
    The Journal of rheumatology · 2001 · Maneiro E et al.  ·  PMID 11764219

醋氯芬酸 —— 原料药与杂质对照品Aceclofenac — drug substance & impurities

共 20 个条目(含原料药本体)20 items incl. the drug substance
Aceclofenac structure
EP原料药 APIAPI
醋氯芬酸Aceclofenac
Aceclofenac
CAS No.89796-99-6
Chemical FormulaC16H13Cl2NO4
Purity>95%询价On request
10mg25mg50mg100mg
Aceclofenac EP Impurity B structure
EPB
双氯芬酸钠杂质17Aceclofenac EP Impurity B
Aceclofenac EP Impurity B
CAS No.15307-78-5
Chemical FormulaC15H13Cl2NO2
Purity>95%询价On request
10mg25mg50mg100mg
Aceclofenac EP Impurity C structure
EPC
双氯芬酸钠杂质18Aceclofenac EP Impurity C
Aceclofenac EP Impurity C
CAS No.15307-77-4
Chemical FormulaC16H15Cl2NO2
Purity>95%询价On request
10mg25mg50mg100mg
Aceclofenac EP Impurity D structure
EPD
醋氯芬酸杂质4(醋氯芬酸EP杂质D)Aceclofenac EP Impurity D
Aceclofenac EP Impurity D
CAS No.139272-66-5
Chemical FormulaC17H15Cl2NO4
Purity>95%询价On request
10mg25mg50mg100mg
Aceclofenac EP Impurity E structure
EPE
醋氯芬酸杂质5(醋氯芬酸EP杂质E)Aceclofenac EP Impurity E
Aceclofenac EP Impurity E
CAS No.139272-67-6
Chemical FormulaC18H17Cl2NO4
Purity>95%询价On request
10mg25mg50mg100mg
Aceclofenac EP Impurity F structure
EPF
醋氯芬酸杂质6(醋氯芬酸EP杂质F)Aceclofenac EP Impurity F
Aceclofenac EP Impurity F
CAS No.100499-89-6
Chemical FormulaC23H19Cl2NO4
Purity>95%询价On request
10mg25mg50mg100mg
Aceclofenac EP Impurity G structure
EPG
醋氯芬酸杂质7(醋氯芬酸EP杂质G)Aceclofenac EP Impurity G
Aceclofenac EP Impurity G
CAS No.1215709-75-3
Chemical FormulaC18H15Cl2NO6
Purity>95%询价On request
10mg25mg50mg100mg
Aceclofenac EP Impurity H structure
EPH
醋氯芬酸杂质8(醋氯芬酸EP杂质H)Aceclofenac EP Impurity H
Aceclofenac EP Impurity H
CAS No.1216495-92-9
Chemical FormulaC20H17Cl2NO8
Purity>95%询价On request
10mg25mg50mg100mg
Aceclofenac tert-Butyl Ester structure
—
醋氯芬酸杂质11(醋氯芬酸叔丁酯)Aceclofenac tert-Butyl Ester
Aceclofenac tert-Butyl Ester
CAS No.139272-68-7
Chemical FormulaC20H21Cl2NO4
Purity>95%询价On request
10mg25mg50mg100mg
4'-Hydroxy Aceclofenac structure
—
醋氯芬酸杂质10(4-羟基醋氯芬酸)4'-Hydroxy Aceclofenac
4'-Hydroxy Aceclofenac
CAS No.229308-90-1
Chemical FormulaC16H13Cl2NO5
Purity>95%询价On request
10mg25mg50mg100mg
N-Nitroso Aceclofenac structure
—
N-Nitroso Aceclofenac
CAS No.—
Chemical FormulaC16H12Cl2N2O5
Purity>95%询价On request
10mg25mg50mg100mg
N-Nitroso Aceclofenac-d4 structure
—
N-Nitroso Aceclofenac-d4
CAS No.—
Chemical FormulaC16H8D4Cl2N2O5
Purity>95%询价On request
Aceclofenac Acyl Glucuronide structure
—
Aceclofenac Acyl Glucuronide
CAS No.—
Chemical FormulaC22H21Cl2NO10
Purity>95%询价On request
10mg25mg50mg100mg
Aceclofenac Impurity 2 structure
2
醋氯芬酸杂质2Aceclofenac Impurity 2
Aceclofenac Impurity 2
CAS No.—
Chemical FormulaC12H16O2
Purity>95%询价On request
10mg25mg50mg100mg
Aceclofenac Impurity 3 structure
3
醋氯芬酸杂质3Aceclofenac Impurity 3
Aceclofenac Impurity 3
CAS No.—
Chemical FormulaC12H15IO2
Purity>95%询价On request
10mg25mg50mg100mg
Aceclofenac Impurity 4 structure
4
醋氯芬酸杂质4Aceclofenac Impurity 4
Aceclofenac Impurity 4
CAS No.—
Chemical FormulaC18H19Cl2NO2
Purity>95%询价On request
10mg25mg50mg100mg
Aceclofenac Impurity 5 structure
5
醋氯芬酸杂质5Aceclofenac Impurity 5
Aceclofenac Impurity 5
CAS No.—
Chemical FormulaC20H21Cl2NO4
Purity>95%询价On request
10mg25mg50mg100mg
Aceclofenac Impurity 18 (N-Nitroso Diclofenac Impurity 6) structure
18
醋氯芬酸杂质18 (N-亚硝基双氯芬酸杂质6)Aceclofenac Impurity 18 (N-Nitroso Diclofenac Impurity 6)
Aceclofenac Impurity 18 (N-Nitroso Diclofenac Impurity 6)
CAS No.3075173-07-5
Chemical FormulaC12H8Cl2N2O
Purity>95%询价On request
10mg25mg50mg100mg
Aceclofenac Impurity 19 structure
19
醋氯芬酸杂质19Aceclofenac Impurity 19
Aceclofenac Impurity 19
CAS No.2514625-79-5
Chemical FormulaC19H19Cl2NO4
Purity>95%询价On request
10mg25mg50mg100mg
Aceclofenac Impurity 21 structure
21
醋氯芬酸杂质21Aceclofenac Impurity 21
Aceclofenac Impurity 21
CAS No.2518198-70-2
Chemical FormulaC22H23Cl2NO6
Purity>95%询价On request
10mg25mg50mg100mg
本品种含亚硝胺类杂质条目。亚硝胺杂质属于 ICH M7 关注的潜在致突变杂质,建议在方法开发中纳入专属性考察。This list includes nitrosamine entries. Nitrosamines are potential mutagenic impurities under ICH M7 and should be covered by a specific method.

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

醋氯芬酸 —— 研究文献与合成路线Aceclofenac — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 醋氯芬酸 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Aceclofenac. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. A New Stability-Indicating RP-HPLC Method for Simultaneous Quantification of Diacerein and Aceclofenac in Novel Nanoemulgel Formulation and Commercial Tablet Dosage Form in the Presence of their Major Degradation Products Using DoE Approach
    Kazi TM, Dandagi PM · Journal of chromatographic science · 2023 · 被引 2cited 2
  2. Stability indicating methods for the determination of aceclofenac
    Hasan NY, Abdel-Elkawy M, Elzeany BE, et al. · Farmaco (Societa chimica italiana : 1989) · 2003 · 被引 7cited 7
  3. RP-LC gradient elution method for simultaneous determination of thiocolchicoside, aceclofenac and related impurities in tablet formulation
    Karbhari PA, Joshi SJ, Bhoir SI · Journal of pharmacy & bioallied sciences · 2014
  4. A simple and sensitive stability-indicating RP-HPLC assay method for the determination of aceclofenac
    Bhinge JR, Kumar RV, Sinha VR · Journal of chromatographic science · 2008 · 被引 18cited 18
  5. Validated stability-indicating assay method for simultaneous determination of aceclofenac and thiocolchicoside using RP-HPLC
    Samanthula G, Shrigod VV, Patel PN · Drug research · 2014 · 被引 2cited 2
  6. Simultaneous determination of aceclofenac, paracetamol, and chlorzoxazone by RP-HPLC in pharmaceutical dosage form
    Shaikh KA, Devkhile AB · Journal of chromatographic science · 2008 · 被引 17cited 17

合成与制备工艺专利Synthesis & process patents

  1. Improved method for preparing aceclofenac
    ZHIQUAN ZHAO, LAN ZHANG · 公开号 CN101531607CN101531607 · 2009
  2. Method for preparing aceclofenac
    XIUGEN WU, HONGYE ZHANG · 公开号 CN101215243CN101215243 · 2008
  3. PROCESS FOR PREPARING ACECLOFENAC AMINOACID SALT
    LEE TAE SUK, YOOK JIN SOO, LEE JONG SOO, YOO CHANG HYUN, et al. · 公开号 KR20070044205KR20070044205 · 2007
  4. Nanoemulsion of aceclofenac for treating rheumatoid arthritis and preparation process thereof
    OUYANG WUQING HE · 公开号 CN1965819CN1965819 · 2007
  5. ACECLOFENAC SLOW-RELEASE PREPARATION PROVIDING AN OPTIMUM PHARMACOLOGICAL CLINICAL EFFECT WHEN ADMINISTERED ONCE A DAY
    LEE BEOM JIN, JUNG WON-TAE, CHOI YOUN WOONG, NAM KYU YEOL, et al. · 公开号 WO2011152652WO2011152652 · 2011

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

醋氯芬酸 杂质谱研究要点Aceclofenac — impurity profiling notes

下面这些是拿到 醋氯芬酸 的 20 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 20 impurity entries for Aceclofenac, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances